MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2024.10.027

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.

Fabi Sabrina, Humphrey Shannon, Biesman Brian, George Rosalyn, LaTowsky Brenda, Weiss Robert A, Park Grace S, Shimoga Sandhya, Lee Elisabeth, Jierjian Edward, Tong Warren, Hopfinger René

СтатьяРандомизированное исследованиеКлиническое исследование III фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Platysma prominence (PP) refers to the undesirable effects that may occur with platysma muscle contraction.

OBJECTIVE

Evaluate safety and efficacy of onabotulinumtoxinA for improving Moderate (Grade 3) to Severe (Grade 4) PP in adults.

METHODS

Participants were randomized 1:1 to receive a total dose of onabotulinumtoxinA 26, 31, or 36 U or placebo on Day 1 and monitored for 120 days. Dosage was administered via superficial intramuscular injections into the platysma muscle based on baseline PP severity.

RESULTS

At Day 14, 32.3% of onabotulinumtoxinA-treated participants in the intent-to-treat population versus 1.9% who received placebo achieved investigator- and participant-rated Grade 1 or 2 (Minimal or Mild) and ≥2-grade improvement from baseline in PP severity, while 56.9% and 51.7% achieved Grade 1 or 2 on investigator's and participant's assessments, respectively (all P < .0001). OnabotulinumtoxinA-treated participants reported higher satisfaction, less bother from jawline and vertical neck band appearance, and reduced psychosocial impact versus placebo (all P < .0001). Adverse event incidence was similar between onabotulinumtoxinA and placebo. No events of dysphagia or muscular weakness were reported.

LIMITATIONS: A single onabotulinumtoxinA treatment was evaluated.

CONCLUSION

OnabotulinumtoxinA showed favorable tolerability and significantly improved PP severity and patient-reported outcomes in participants with moderate-to-severe PP.

Для цитирования: Fabi Sabrina, Humphrey Shannon, Biesman Brian, George Rosalyn, LaTowsky Brenda, Weiss Robert A, Park Grace S, Shimoga Sandhya, Lee Elisabeth, Jierjian Edward, Tong Warren, Hopfinger René. Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2024.10.027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.